Celgene on the Verge of Buy Signal, New Highs

CELG is in a long-term bull channel with support at its 50-day moving average

   
Celgene on the Verge of Buy Signal, New Highs

Celgene (CELG) — This company develops small molecule drugs for the treatment of blood-borne and solid-tumor cancers and inflammatory diseases. The stock was on my list of Top Stocks to Buy for December, near $81 (post 2-for-1 split), and has been on the Trade of the Day buy list for over a year.

CELG succumbed to the sell-off in the biotech sector, hitting a low under $70 in mid-April, but has since recovered and made new all-time highs.

S&P has a “strong buy” rating on shares with a target of $104. It recently raised its earnings estimate for 2014 to $3.64 from $3.60. Adjusted Q2 EPS came in above its target at $0.90 versus an expected $0.86.

Following the shake-out of the industry in March and April, CELG formed a huge cup-and-handle and is in a powerful long-term bull channel with initial support at its 50-day moving average at $85.48. Near term, the stock has found support there and should shortly trigger a buy signal from MACD.

CELG has an excellent chance of breaking to a new high above $90.50. The trading target is $110, but investors could do much better by holding this high-quality biotech long term.

08 14 14 celg 300x180 Celgene on the Verge of Buy Signal, New Highs
Click to Enlarge

chart key 300x84 Celgene on the Verge of Buy Signal, New Highs


Article printed from InvestorPlace Media, http://investorplace.com/2014/08/trade-day-celgene-celg-3/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.